3’-甲酰(1,1’-联苯)-3-羧酸 | 222180-19-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3’-甲酰(1,1’-联苯)-3-羧酸
• 中文别名: 3'-甲酰(1,1'-联苯)-3-羧酸
• 英文名称: 3'-formyl(1,1'-biphenyl)-3-carboxylic acid
• 英文别名: 3'-Formyl-[1,1'-biphenyl]-3-carboxylic acid；3-(3-formylphenyl)benzoic acid
• CAS: 222180-19-0
• 化学式: C₁₄H₁₀O₃
• 分子量: 226.232
• InChiKey: QOCUSJPHQSKJJR-UHFFFAOYSA-N

物化性质

• 熔点：
  174 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2918300090
• 储存条件：
  应存于室温、避光且处于惰性气氛中保存。

SDS

Name:	3 -Formyl[1 1 -biphenyl]-3-carboxylic acid Material Safety Data Sheet
Synonym:	None Known
CAS:	222180-19-0

Section 1 - Chemical Product MSDS Name:3 -Formyl[1 1 -biphenyl]-3-carboxylic acid Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
222180-19-0	3'-Formyl[1,1'-biphenyl]-3-carboxylic	97+	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. Harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse. Keep from contact with moist air and steam.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store protected from moisture. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 222180-19-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 173.5-174.5 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H10O3
Molecular Weight: 226.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation, moisture.
Incompatibilities with Other Materials:
Oxidizing agents, alcohols, amines, bases.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 222180-19-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3'-Formyl[1,1'-biphenyl]-3-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 6 Keep under nitrogen.
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 222180-19-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 222180-19-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 222180-19-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-丙烯基洛丹宁 、 3’-甲酰(1,1’-联苯)-3-羧酸 在 ethylenediamine Tetraacetic Acid 作用下， 以 甲醇 为溶剂， 反应 18.0h， 以54%的产率得到3-[3-[(Z)-(4-oxo-3-prop-2-enyl-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]phenyl]benzoic acid
  参考文献：
  名称：

  Structure−Activity Relationships of Phenyl-Furanyl-Rhodanines as Inhibitors of RNA Polymerase with Antibacterial Activity on Biofilms

  摘要：

  The dramatic rise of antibiotic-resistant bacteria over the past two decades has stressed the need for completely novel classes of antibacterial agents. Accordingly, recent advances in the study of prokaryotic transcription open new opportunities for such molecules. This paper reports the structure-activity relationships of a series of phenyl-furanyl-rhodanines (PFRs) as antibacterial inhibitors of RNA polymerase (RNAP). The molecules have been evaluated for their ability to inhibit transcription and affect growth of bacteria living in suspension or in a biofilm and for their propensity to interact with serum albumin, a critical parameter for antibacterial drug discovery. The most active of these molecules inhibit Escherichia coli RNAP transcription at concentrations of <= 10 mu M and have promising activities against various Gram-positive pathogens including Staphylococcus epidermidis biofilms, a major cause of nosocomial infection.

  DOI：

  10.1021/jm0703183

文献信息

• 4-Amino-1,2,4-triazole-3-thione-derived Schiff bases as metallo-β-lactamase inhibitors
  作者：Laurent Gavara、Laurent Sevaille、Filomena De Luca、Paola Mercuri、Carine Bebrone、Georges Feller、Alice Legru、Giulia Cerboni、Silvia Tanfoni、Damien Baud、Giuliano Cutolo、Benoît Bestgen、Giulia Chelini、Federica Verdirosa、Filomena Sannio、Cecilia Pozzi、Manuela Benvenuti、Karolina Kwapien、Marina Fischer、Katja Becker、Jean-Marie Frère、Stefano Mangani、Nohad Gresh、Dorothée Berthomieu、Moreno Galleni、Jean-Denis Docquier、Jean-François Hernandez

  DOI：10.1016/j.ejmech.2020.112720

  日期：2020.12

  potent, they represented a promising basis for the development of broad-spectrum MBL inhibitors. Here, we synthesized and characterized a large number of 4-amino-1,2,4-triazole-3-thione-derived Schiff bases. Compared to the previous series, the presence of an aryl moiety at position 4 afforded an average 10-fold increase in potency. Among 90 synthetic compounds, more than half inhibited at least one

  产生金属β-内酰胺酶（MBL）的革兰氏阴性菌对β-内酰胺抗生素的耐药性代表着重大的医学威胁，并且迫切需要开发临床上有用的抑制剂。我们先前报道了MBL催化位点中的5个取代的4-氨基/ H-1,2,4-三唑-3-硫酮化合物的原始结合模式。此外，我们表明，尽管具有中等效力，但它们代表了广谱MBL抑制剂开发的有希望的基础。在这里，我们合成和表征了大量的4-氨基-1,2,4-三唑-3-硫酮衍生的席夫碱。与先前的系列相比，在4位上存在芳基部分可使效力平均提高10倍。在90种合成化合物中，超过一半的化合物抑制了至少六个被测MBL（L1，VIM-4，VIM-2，NDM-1，IMP-1，K i的值在μM至亚μM范围内。几种是广谱抑制剂，也可以抑制临床上最相关的VIM-2和NDM-1。活性化合物通常在位置5处包含卤代，双环芳基或酚基部分，以及在邻苯甲酸，2,4-二羟基苯基，对苄氧基苯基或3-（m-苯甲酰基）-
• Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay
  作者：Zhongjie Liang、Xiao Ding、Jing Ai、Xiangqian Kong、Limin Chen、Liang Chen、Cheng Luo、Meiyu Geng、Hong Liu、Kaixian Chen、Hualiang Jiang

  DOI：10.1039/c1ob06186k

  日期：——

  A substructure similarity search against the SPECS database and chemical synthesis methods were performed to obtain a series of pyrazolidine-3,5-dione derivatives. Through the enzyme-based assay against c-Met kinase, 4 compounds (1c, 1e, 1m and 1o) showed potential inhibitory activity, with IC50 values mostly less than 10 μM. Based on the structure–activity relationship (SAR) and binding mode analysis

  受体酪氨酸激酶c-Met是当今治疗癌症的诱人靶标。小分子抑制剂的发现在c-Met激酶途径的阻断中特别有意义。在这里，我们从化合物1a开始研究，化合物1a是一种新型的c-Met激酶抑制剂。针对SPECS数据库的子结构相似性搜索和化学合成方法，获得了一系列吡唑烷-3,5-二酮衍生物。通过针对c-Met激酶的基于酶的测定，四种化合物（1c，1e，1m和1o）显示出潜在的抑制活性，IC 50值通常小于10μM。基于结构-活性关系（SAR）和结合模式分析，LD1.0程序设计了一个有针对性的组合库。考虑到ADMET的性质和可合成性，成功合成了七个候选化合物（5a–g）。最有效的化合物5b（IC 50 = 0.46μM）的活性是铅1a的20倍。综上所述，我们的发现确定吡唑烷-3,5-二酮衍生物是抗c-Met激酶的有效抑制剂，并证明了该策略在开发抗c-Met激酶的小分子中的有效性。
• DNA-ENCODED CHEMICAL LIBRARY, USE THEREOF, AND METHOD TO SYNTHESIZE THE LIBRARY
  申请人：Technische Universität Dortmund

  公开号：EP3885437A1

  公开（公告）日：2021-09-29

  The present invention relates to a compound library comprising a plurality of conjugate molecules, wherein said conjugates comprise a small organic molecule covalently coupled to a nucleic acid moiety, wherein the nucleic acid moiety comprises or consists of 7-deazapurines and/or 7-deaza-8-azapurines, and, optionally, modified and/or unmodified pyrimidine nucleotides. Further, the present invention relates to the use of said library for screening compounds binding to a target molecule and methods of synthesizing said library.

  本发明涉及一种由多个共轭分子组成的化合物库，其中所述共轭分子包括与核酸分子共价偶联的小有机分子，所述核酸分子包括或由7-脱氮杂嘌呤和/或7-脱氮杂-8-氮杂嘌呤组成，以及可选的修饰和/或未修饰的嘧啶核苷酸。此外，本发明还涉及使用所述文库筛选与靶分子结合的化合物以及合成所述文库的方法。
• Selective aerobic oxidation of dimethylbiphenyls
  申请人：ExxonMobil Research and Engineering Company

  公开号：US10287230B2

  公开（公告）日：2019-05-14

  A process for selective oxidation of dimethyl-1,1′-biphenyl(s) to form methyl-1,1′-biphenyl mono-carboxylic acid(s), which can be esterified to form plasticizers, comprising contacting a solution of dimethyl-1,1′-biphenyl(s) in acetic acid in the presence of an oxidation catalyst and air under time and temperature conditions sufficient to oxidize the dimethyl-1,1′-biphenyl(s) into one or more methyl-1,1′-biphenyl mono-carboxylic acid(s) products, conducting at least one of (i) adding an antisolvent, or (ii) optimizing a total conversion of dimethyl-1,1′-biphenyl(s) by oxidation based upon a molar ratio of dimethyl-1,1′-biphenyl isomers, or (iii) precipitating the methyl-1,1′-biphenyl mono-carboxylic acid(s) products by lowering the temperature, or (iv) decreasing the oxidation reaction temperature to enhance conversion of aldehydes over methyl functional groups, so as to limit over-oxidation of the dimethyl-1,1′-biphenyl(s), wherein the oxidation reaction is conducted in the absence of bromide-containing catalysts.

  一种选择性氧化二甲基-1,1′-联苯以形成甲基-1,1′-联苯单羧酸（s）的工艺，其可酯化形成增塑剂，包括将二甲基-1、1，1′-联苯（s）在乙酸中的溶液，在氧化催化剂和空气存在下，在足以将二甲基-1，1′-联苯（s）氧化成一种或多种甲基-1，1′-联苯单羧酸（s）产物的时间和温度条件下，进行以下至少一种反应：(i) 添加抗溶剂、或 (ii) 根据二甲基-1,1′-联苯异构体的摩尔比，通过氧化优化二甲基-1,1′-联苯（s）的总转化率，或 (iii) 通过降低温度沉淀甲基-1,1′-联苯单羧酸（s）产物、或(iv)降低氧化反应温度，以提高醛对甲基官能团的转化，从而限制二甲基-1,1′-联苯的过度氧化，其中氧化反应是在没有含溴催化剂的情况下进行的。
• Cramer, Richard D.; Poss, Michael A.; Hermsmeier, Mark A., Journal of Medicinal Chemistry, 1999, vol. 42, # 19, p. 3931 - 3933
  作者：Cramer, Richard D.、Poss, Michael A.、Hermsmeier, Mark A.、Caulfield, Thomas J.、Kowala, Mark C.、Valentine, Maria T.

  DOI：——

  日期：——